Back to Search
Start Over
Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma.
- Source :
-
Anticancer research [Anticancer Res] 2017 Dec; Vol. 37 (12), pp. 6839-6843. - Publication Year :
- 2017
-
Abstract
- Background/aim: Stage I splenic diffuse large B-cell lymphoma (DLBCL) is rare and there are few data to guide management. We sought to further define prognosis and outcomes.<br />Materials and Methods: We utilized the Surveillance, Epidemiology, and End Results registry to identify patients with stage I splenic DLBCL diagnosed 1973-2013. Patients were divided into two cohorts based on the year of diagnosis (1983-2005; 2006-2013) as rituximab was approved by the U.S. Food and Drug Administration in 2006 for first-line treatment of DLBCL.<br />Results: Utilization of splenectomy decreased after the approval of rituximab (82% pre- versus 72% rituximab-era). Disease-specific and overall survival were greater with splenectomy [hazard ratio (HR)=0.57, p=0.04; and HR=0.66, p=0.03, respectively], but this benefit was only seen in the pre-rituximab cohort, not in the rituximab-era cohort. There was a trend toward improved overall survival with the introduction of rituximab (HR=0.75, p=0.054).<br />Conclusion: Utilization of splenectomy for stage I splenic DLBCL has decreased with the introduction of rituximab without compromising outcomes.<br /> (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Subjects :
- Antineoplastic Agents, Immunological therapeutic use
Cohort Studies
Combined Modality Therapy
Disease-Free Survival
Humans
Lymphoma, Large B-Cell, Diffuse pathology
Lymphoma, Large B-Cell, Diffuse surgery
Neoplasm Staging
Outcome Assessment, Health Care methods
Outcome Assessment, Health Care statistics & numerical data
Proportional Hazards Models
Splenectomy methods
Splenic Neoplasms pathology
Splenic Neoplasms surgery
United States
Lymphoma, Large B-Cell, Diffuse drug therapy
Rituximab therapeutic use
SEER Program statistics & numerical data
Splenic Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1791-7530
- Volume :
- 37
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Anticancer research
- Publication Type :
- Academic Journal
- Accession number :
- 29187463
- Full Text :
- https://doi.org/10.21873/anticanres.12145